Post-earnings recap
Reported
Wed, Mar 13, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.07 per share, which did not meet expectations, but the stock rose by 3.38%. This increase may reflect investor optimism about the company's ongoing clinical programs despite the lack of specific revenue guidance. The market reaction suggests that investors are still confident in the company's long-term potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management's commentary indicated a focus on ongoing clinical development without providing specific financial guidance. The tone was neutral, reflecting the company's current position.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs.